Q3 EPS Estimate for United Therapeutics Reduced by Analyst

United Therapeutics Co. (NASDAQ:UTHR - Free Report) - Equities research analysts at Zacks Research decreased their Q3 2025 EPS estimates for shares of United Therapeutics in a research note issued on Tuesday, May 20th. Zacks Research analyst R. Department now expects that the biotechnology company will earn $6.48 per share for the quarter, down from their previous estimate of $6.95. The consensus estimate for United Therapeutics' current full-year earnings is $24.48 per share. Zacks Research also issued estimates for United Therapeutics' Q4 2025 earnings at $6.30 EPS, FY2025 earnings at $25.64 EPS and Q1 2026 earnings at $6.75 EPS.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last released its quarterly earnings results on Wednesday, April 30th. The biotechnology company reported $6.63 EPS for the quarter, beating analysts' consensus estimates of $6.29 by $0.34. The firm had revenue of $794.40 million for the quarter, compared to analyst estimates of $726.82 million. United Therapeutics had a net margin of 40.31% and a return on equity of 19.22%. The company's revenue for the quarter was up 17.2% compared to the same quarter last year. During the same period in the previous year, the business earned $6.17 earnings per share.

Several other equities analysts also recently issued reports on the company. StockNews.com downgraded United Therapeutics from a "strong-buy" rating to a "buy" rating in a research report on Friday, May 2nd. Bank of America raised United Therapeutics from an "underperform" rating to a "neutral" rating and set a $314.00 price target for the company in a report on Monday, April 21st. Wells Fargo & Company reiterated an "equal weight" rating and set a $314.00 price target (down previously from $395.00) on shares of United Therapeutics in a research report on Friday, April 25th. HC Wainwright reissued a "buy" rating and set a $425.00 price objective on shares of United Therapeutics in a report on Monday, May 5th. Finally, Morgan Stanley boosted their target price on shares of United Therapeutics from $346.00 to $348.00 and gave the stock an "equal weight" rating in a research note on Thursday, May 1st. Four equities research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $392.00.

United Therapeutics Trading Up 0.0%

NASDAQ:UTHR opened at $309.68 on Thursday. The stock has a market capitalization of $13.97 billion, a P/E ratio of 13.60, a price-to-earnings-growth ratio of 0.97 and a beta of 0.58. United Therapeutics has a 1 year low of $264.33 and a 1 year high of $417.82. The firm has a 50 day moving average of $300.05 and a 200-day moving average of $339.31.

Insider Buying and Selling at United Therapeutics

In other news, COO Michael Benkowitz sold 10,000 shares of United Therapeutics stock in a transaction on Monday, February 24th. The shares were sold at an average price of $360.76, for a total transaction of $3,607,600.00. Following the transaction, the chief operating officer now directly owns 2,577 shares of the company's stock, valued at $929,678.52. This trade represents a 79.51% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP Paul A. Mahon sold 11,000 shares of the company's stock in a transaction on Thursday, May 1st. The shares were sold at an average price of $300.93, for a total transaction of $3,310,230.00. Following the completion of the sale, the executive vice president now owns 36,781 shares of the company's stock, valued at approximately $11,068,506.33. This represents a 23.02% decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 55,500 shares of company stock valued at $17,054,780. 10.30% of the stock is currently owned by insiders.

Institutional Investors Weigh In On United Therapeutics

A number of hedge funds have recently modified their holdings of the business. Wealthfront Advisers LLC raised its holdings in United Therapeutics by 2,090,573.5% during the 4th quarter. Wealthfront Advisers LLC now owns 18,314,300 shares of the biotechnology company's stock worth $6,462,018,000 after buying an additional 18,313,424 shares during the period. Norges Bank acquired a new position in shares of United Therapeutics in the fourth quarter valued at approximately $151,764,000. FMR LLC increased its position in shares of United Therapeutics by 36.5% during the fourth quarter. FMR LLC now owns 1,471,405 shares of the biotechnology company's stock worth $519,170,000 after acquiring an additional 393,777 shares in the last quarter. Vaughan Nelson Investment Management L.P. acquired a new stake in shares of United Therapeutics during the first quarter worth $101,354,000. Finally, Nuveen LLC bought a new stake in United Therapeutics in the 1st quarter valued at $83,533,000. Institutional investors and hedge funds own 94.08% of the company's stock.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.